Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematologic disorder characterized by complement-mediated hemolysis. C5 inhibitors (eculizumab/ravulizumab) control intravascular hemolysis but do not prevent residual extravascular hemolysis. The newly approved complement inhibitor, pegc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of hematology 2022-09, Vol.101 (9), p.1971-1986
Hauptverfasser:	Wong, Raymond S. M., Pullon, Humphrey W. H., Amine, Ismail, Bogdanovic, Andrija, Deschatelets, Pascal, Francois, Cedric G., Ignatova, Kalina, Issaragrisil, Surapol, Niparuck, Pimjai, Numbenjapon, Tontanai, Roman, Eloy, Sathar, Jameela, Xu, Raymond, Al-Adhami, Mohammed, Tan, Lisa, Tse, Eric, Grossi, Federico V.
Format:	Artikel
Sprache:	eng
Schlagworte:	Anemia Blood diseases Bone marrow Dehydrogenases Drug dosages FDA approval Hematology Hemoglobin Hospitals Medicine Medicine & Public Health Monoclonal antibodies Oncology Original Original Article Pharmaceuticals Quality of life
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!